Vibativ

Vibativ is a brand name of telavancin, approved by the FDA in the following formulation(s):

VIBATIV (telavancin hydrochloride - powder; iv (infusion))

• 
  Manufacturer: THERAVANCE INC
  
  Approval date: September 11, 2009
  
  Strength(s): EQ 250MG BASE/VIAL, EQ 750MG BASE/VIAL ^[RLD]

Has a generic version of Vibativ been approved?

No. There is currently no therapeutically equivalent version of Vibativ available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vibativ. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Glycopeptide phosphonate derivatives
  Patent 6,635,618
  Issued: October 21, 2003
  Inventor(s): Michael R.; Leadbetter & Martin S.; Linsell
  Assignee(s): Theravance, Inc.
  Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
  
  Patent expiration dates:
  
  
  • September 22, 2021
    
    ✓ 
    Patent use: METHOD FOR TREATING BACTERIAL INFECTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
  Patent 6,858,584
  Issued: February 22, 2005
  Inventor(s): Judice; J. Kevin & Shaw; Jeng-Pyng & Mu; YongQi & Conner; Michael W. & Pace; John L.
  Assignee(s): Theravance, Inc.
  Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
  
  Patent expiration dates:
  
  
  • August 24, 2022
    
    ✓ 
    Drug product
  
  



• 
  Glycopeptide phosphonate derivatives
  Patent 6,872,701
  Issued: March 29, 2005
  Inventor(s): Leadbetter; Michael R. & Linsell; Martin S.
  Assignee(s): Theravance, Inc.
  Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
  
  Patent expiration dates:
  
  
  • June 5, 2021
    
    ✓ 
    Drug product
  
  



• 
  Glycopeptide phosphonate derivatives
  Patent 7,008,923
  Issued: March 7, 2006
  Inventor(s): Leadbetter; Michael R. & Linsell; Martin S.
  Assignee(s): Theravance, Inc.
  Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
  
  Patent expiration dates:
  
  
  • May 6, 2021
    
    ✓ 
    Patent use: METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
  
  



• 
  Glycopeptide phosphonate derivatives
  Patent 7,208,471
  Issued: April 24, 2007
  Inventor(s): Leadbetter; Michael R.
  Assignee(s): Theravance, Inc.
  Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
  
  Patent expiration dates:
  
  
  • May 1, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Glycopeptide phosphonate derivatives
  Patent 7,351,691
  Issued: April 1, 2008
  Inventor(s): Leadbetter; Michael R. & Linsell; Martin S.
  Assignee(s): Theravance, Inc.
  Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
  
  Patent expiration dates:
  
  
  • May 1, 2021
    
    ✓ 
    Patent use: METHOD FOR TREATING BACTERIAL INFECTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Hydrochloride salts of a glycopeptide phosphonate derivative
  Patent 7,531,623
  Issued: May 12, 2009
  Inventor(s): Liu; Jyanwei & Lee; Junning
  Assignee(s): Theravance, Inc.
  Disclosed are hydrochloride salts of telavancin having a chloride ion content of from about 2.4 wt. % to about 4.8 wt. %. The disclosed salts have improved stability during storage at ambient temperatures compared to other hydrochloride salts. Also disclosed are processes for preparing such salts.
  
  Patent expiration dates:
  
  
  • January 1, 2027
    
    ✓ 
    Drug substance
  
  



• 
  Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
  Patent 7,544,364
  Issued: June 9, 2009
  Inventor(s): Judice; J. Kevin & Shaw; Jeng-Pyng & Mu; YongQi & Conner; Michael W. & Pace; John L.
  Assignee(s): Theravance, Inc.
  Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
  
  Patent expiration dates:
  
  
  • May 1, 2021
    
    ✓ 
    Drug product
  
  



• 
  Glycopeptide phosphonate derivatives
  Patent 7,700,550
  Issued: April 20, 2010
  Inventor(s): Leadbetter; Michael R.
  Assignee(s): Theravance, Inc.
  Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
  
  Patent expiration dates:
  
  
  • May 1, 2021
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 11, 2014 - NEW CHEMICAL ENTITY
  
  

See also...

• Vibativ Consumer Information (Drugs.com)
• Vibativ Consumer Information (Wolters Kluwer)
• Vibativ Consumer Information (Cerner Multum)
• Vibativ Advanced Consumer Information (Micromedex)
• Vibativ AHFS DI Monographs (ASHP)
• Telavancin Consumer Information (Wolters Kluwer)
• Telavancin Consumer Information (Cerner Multum)
• Telavancin Intravenous Advanced Consumer Information (Micromedex)
• Telavancin Hydrochloride AHFS DI Monographs (ASHP)